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Background: Small ubiquitin-related modifier (SUMO) is a group of proteins that participates in post-translational
modifications. One known SUMO target is the transcription factor nuclear factor-kB (NF-kB) that plays a pivotal role
in many disease processes; sumoylation inactivates NF-kB by conjugation with inhibitors of NF-kB (IkB). Our
laboratory demonstrated previously that transcriptional upregulation of nitric oxide synthase II (NOS II) by NF-kB,
leading to nitrosative stress by the formation of peroxynitrite in the rostral ventrolateral medulla (RVLM), underpins
the defunct brain stem cardiovascular regulation that precedes brain death. Based on an experimental endotoxemia
model, this study evaluated the hypothesis that sumoylation plays a pro-life role in brain death by interacting with
the NF-kB/NOS II/peroxynitrite signaling pathway in the RVLM.
Results: In Sprague–Dawley rats, intravenous administration of Escherichia coli lipopolysaccharide (LPS; 10 mg kg−1)
elicited an augmentation of SUMO-1 and ubiquitin-conjugase 9 (Ubc9) mRNA or protein levels, alongside SUMO-1-
conjugated proteins in the RVLM. Immunoneutralization of SUMO-1 or Ubc9 in the RVLM significantly potentiated the
already diminished sumoylation of IkBα and intensified NF-kB activation and NOS II/peroxynitrite expression in this brain
stem substrate, together with exacerbated fatality, cardiovascular depression and reduction of an experimental index of a
life-and-death signal detected from arterial pressure that disappears in comatose patients signifying failure of brain stem
cardiovascular regulation before brain death.
Conclusion: We conclude that sumoylation of IkB in the RVLM ameliorates the defunct brain stem cardiovascular
regulation that underpins brain death in our experimental endotoxemia modal by reducing nitrosative stress via
inhibition of IkB degradation that diminishes the induction of the NF-kB/NOS II/peroxynitrite signaling cascade.
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Defunct brain stem cardiovascular regulationBackground
Small ubiquitin-related modifier (SUMO) is a group of
proteins identified about two decades ago [1, 2] that
participates in post-translational modifications. Despite
the name, SUMO shares only about 18–20 % homology
with ubiquitin and is approximately 11 kDa in molecular
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and −3 share 95 % homology with each other, but only
50 % identity with SUMO-1 [4–6]; SUMO-4 shares 87 %
amino acid similarity with SUMO-2 [6]. Sumoylation in-
volves the covalent attachment of a member of the
SUMO proteins to lysine residues in the target proteins.
The process of sumoylation is very similar to ubiquitina-
tion and other ubiquitin-like proteins [4], and involves
four enzymatic steps: maturation, activation, conjugation
and ligation [7]. All SUMO proteins share the same acti-
vating (E1) and conjugating (E2) enzymes. Importantly,le is distributed under the terms of the Creative Commons Attribution 4.0
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zyme [6, 8].
One of the known SUMO targets is nuclear factor-kB
(NF-kB) [9–12], an important transcription factor that
regulates many immune and inflammatory genes and
plays a pivotal role in lethal endotoxemia [13]. The NF-
kB family in mammals consists of five proteins, p65
(RelA), RelB, c-Rel, p50 and p52, which can form tran-
scriptionally active homo- or heterodimers [14, 15]. NF-
kB is retained in a latent form in the cytoplasm of non-
stimulated cells by inhibitory molecules collectively
termed inhibitors of NF-kB (IkB). Stimuli that induce
NF-kB activation target IkB to degradation via a phos-
phorylation- dependent ubiquitination process [16]. Fol-
lowing IkB degradation, NF-kB is translocated to the
nucleus as an active transcription factor that is able to
induce its target genes [17, 18]. On the other hand,
sumoylation can inactivate NF-kB by conjugation with
IkB [19, 20]. The sumoylated pool of IkB is protected
from ubiquitination, thereby blocking its degradation
and inhibits subsequent activation and nuclear trans-
location of NF-kB [9].
Our laboratory reported previously that one unique
prognostic phenotype for brain death exists in the low-
frequency (BLF) component (0.04-0.15 Hz in human) of
the systemic arterial pressure spectrum [21]. The power
density of the BLF component, which reflects the pre-
vailing baroreflex-mediated sympathetic vasomotor tone
[22], invariably exhibits a dramatic reduction or loss be-
fore brain death ensues in comatose patients who suc-
cumbed to systemic inflammatory response syndrome
[23], severe brain injury [24] or organophosphate poi-
soning [25]. We further demonstrated that this life-and-
death signal originates from the rostral ventrolateral me-
dulla (RVLM) [26], which is known classically for its role
in tonic maintenance of sympathetic vasomotor tone
and blood pressure [27]. It follows that this brain stem
site is a suitable neural substrate for mechanistic delin-
eation of brain death [21]. In an endotoxemia model of
brain death, our laboratory showed previously that the
progression towards brain death is causally related to
transcriptional upregulation of nitric oxide synthase II
(NOS II) induced by NF-kB in the RVLM [28–30]. The
eventual fatal culprit is nitrosative stress elicited by the
formation of peroxynitrite via a reaction between NOS
II-produced nitric oxide (NO) and superoxide anion in
the RVLM, of which underpins the loss of BLF power
that precedes hypotension and asystole during the pro-
gression towards brain death [30, 31].
The present study assessed the guiding hypothesis that
sumoylation plays a pro-life role by interacting with the
NF-kB/NOS II/peroxynitrite signaling pathway in the
RVLM during brain death. Based on an experimental
endotoxemia model of brain death, our combinedbiochemical, physiological and pharmacological results
validated this hypothesis. We demonstrated that sumoyla-
tion of IkB in the RVLM ameliorates the defunct brain
stem cardiovascular regulation during experimental brain
death by reducing nitrosative stress via inhibition of IkB
degradation that diminishes the induction of the NF-kB/
NOS II/peroxynitrite signaling cascade.
Methods
Experimental animals
Adult, male Sprague–Dawley rats (202 to 280 g; n = 286)
purchased from BioLASCO or the Experimental Animal
Center of the Ministry of Science and Technology,
Taiwan, were used. Animas were housed in an AAALAC
International-accredited Center for Laboratory Animals,
with maintained room temperature (24 ± 1 °C) and 12-h
light–dark cycle (lights on during 07:00–19:00). Animals
were allowed to acclimatize for at least 7 days prior to
experimental manipulations. Standard laboratory rat
chow and tap water were available ad libitum.
General preparation
Under an induction anesthesia by pentobarbital sodium
(50 mg kg−1, i.p.), the trachea was intubated and one
femoral artery and both femoral veins were cannulated.
During the recording session, anesthesia was maintained
by intravenous infusion of propofol (Fresenius Kabi,
Austria) at 20–25 mg kg−1 h−1. Based on spectral ana-
lysis of arterial pressure (AP) signals and nociceptive
tests, our laboratory has demonstrated [32] that this
scheme provides satisfactory anesthetic maintenance
while preserving the capacity of central cardiovascular
regulation. The head of animals was thereafter fixed to a
stereotaxic headholder (Kopf, Tujunga, CA), and the
body temperature was maintained at 37 °C with a heat-
ing pad. During the recording session, animals were
allowed to breathe spontaneously with room air.
Recording and power spectral analysis of systemic arterial
pressure signals
AP signals recorded from the femoral artery were proc-
essed by an acquisition algorithm at a rate of 1,000 Hz
(Notocord, Croissy Sur Seine, France). The digitized
signals were analyzed by an arterial blood pressure
analyzer (APR31a, Notocord); and were subject to con-
tinuous, on-line, and real-time spectral analysis (SPA10a,
Notocord) [33, 34]. We were particularly interested in
the BLF (0.25-0.8 Hz) band of the AP spectrum for three
reasons. First, this spectral component takes origin from
the RVLM [26]. Second, it reflects the prevalence of
baroreflex-mediated sympathetic vasomotor tone that
emanates from this brain stem site [22]. Third and most
importantly, the power density of the BLF component
represents the crucial link between our animal model
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temic inflammatory response syndrome [23], and is a
more sensitive prognostic index than AP for brain death
[21]. Heart rate (HR) was derived instantaneously from
the AP signals.
Experimental endotoxemia model of brain death
An experimental endotoxemia model of brain death
[21], which mimics clinically the progression towards
brain death in patients died of systemic inflammatory
response syndrome [23] was used. Escherichia coli lipo-
polysaccharide (LPS; 0111:B4 strain; InvivoGen, San
Diego, CA) was administrated intravenously at 10 mg kg−1
[30], with saline serving as the vehicle control. Temporal
changes in pulsatile AP, mean AP (MAP), HR and
power density of the BLF component were routinely
followed for 300 min, or until the animal succumbed
to endotoxemia. The survival rate within 300 min was
also recorded.Microinjection of test agents into the RVLM
Test agents were microinjected bilaterally and sequen-
tially into the RVLM, at a volume of 50 nL, via a glass
micropipette connected to a 0.5-μL Hamilton microsyr-
inge (Reno, NV). The coordinates used were 4.5 to
5 mm posterior to the lambda, 1.8 to 2.1 mm lateral to
midline, and 8.1 to 8.4 mm below the dorsal surface of
cerebellum [28, 33, 34]. Test agents used in this study
included a polyclonal antiserum against SUMO-1 (Cell
Signaling Technology, Beverly, MA) generated by im-
munizing rabbits with a synthetic peptide corresponding
to a sequence within SUMO-1 that does not correspond
to SUMO-2/3, or a mouse monoclonal antiserum against
Ubc9 (BD Biosciences, San Jose, CA). Possible volume ef-
fect of microinjection was controlled by injecting the same
amount of normal rabbit serum (NRS) or normal mouse
serum (NMS) (Sigma-Aldrich, St. Louis, MO). As in our
previous studies [34, 35], 0.02 % Triton X-100 (Sigma-Al-
drich) was added to facilitate transport of the antiserum,
NRS or NMS across the cell membrane of RVLM neu-
rons. All test agents were microinjected bilaterally into the
RVLM 30 min before LPS administration. To avoid the
confounding effects of drug interactions, each animal re-
ceived only LPS or saline plus one test agent.
Collection of tissue samples from the RVLM
We routinely collected tissue samples [29–31] at the
peak of each phase of experimental endotoxemia (LPS
group), or 20, 150 or 300 min after intravenous injection
of saline (saline group). Medullary tissues collected from
anesthetized animals but without treatment served as
the sham-controls. As a routine, microinjection sites
were visually verified and recorded after the slice ofmedulla oblongata that contains the RVLM (0.5 to
1.5 mm rostral to the obex) was obtained. Tissues
from both sides of the ventrolateral medulla were
subsequently collected by micropunches made with a
1 mm (i.d.) stainless steel bore to cover the anatom-
ical boundaries of the RVLM. The samples were
stored immediately in liquid nitrogen.
Isolation of RNA and real-time PCR
Total RNA from the RVLM was isolated with a Total RNA
Mini kit (Geneaid, Taipei, Taiwan). All RNA isolated was
quantified by spectrophotometry and the optical density
260/280 nm ratio was determined. As in our previous stud-
ies [34, 36, 37], reverse transcriptase reaction was per-
formed using a Transcriptor First strand cDNA Synthesis
kit (Roche, Mannheim, Germany). Real-time PCR analysis
was performed by amplification of cDNA using a LightCy-
cler (Roche). Genes were quantified by SYBR Green real-
time polymerase chain reaction with gapdh as the endogen-
ous control. Primers were designed by Roche LightCycler
probe design software 2.0 using the sequence information
of the NCBI database, and oligonucleotides were synthe-
sized by Quality Systems (Taipei, Taiwan). The primer pairs
used for amplification of the target genes were:
sumo1 (Genbank Accession: NM_001009672):
Forward primer: 5′-TGTCTGACCAGGAGGCA-3′
Reverse primer: 5′-ACAGTACGATTCTTTGAGCTT-3′
ubc9 (Genbank Accession: NM_001180123):
Forward primer: 5′-TTTCCGCCACTGGCATA-3′
Reverse primer: 5′-AGCGGACGAGAAGAAACTA-3′




The relative changes in mRNA expression were deter-
mined by the fold-change analysis, in which fold change
= 2−[ΔΔCt], where ΔΔCt = (Ctgene −Ctgapdh) LPS or saline
treatment − (Ctgene −Ctgapdh) sham control). Note that Ct
value is the cycle number at which fluorescence signal
crosses the threshold.
Protein extraction and western blot analysis
As in previous studies [33, 34, 37], tissue samples
from RVLM were homogenized on ice in a protein
extraction buffer that contains protease and phosphat-
ase inhibitors, and centrifuged at 10,000 g at 4 °C for
10 min. The concentration of total proteins was de-
termined by the BCA protein assay (Pierce, Rockford,
IL), and absorbance was measured at 562 nm.
Western blot analysis was carried out using a rabbit
polyclonal antiserum against SUMO-1 (Cell Signaling)
or NOS II (Santa Cruz Biotechnology, Santa Cruz,
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(BD Biosciences), IkBα (Cell Signaling), nitrotyrosine
(Upstate, Lake Placid, NY) or β-actin (Chemicon).
This was followed by incubation with horseradish
peroxidase-conjugated donkey anti-rabbit IgG (GE
Healthcare, Little Chalfont, Buckinghamshire, UK), or
sheep anti-mouse IgG (GE Healthcare). Specific
antibody-antigen complex was detected using an en-
hanced chemiluminescence western blot detection sys-
tem (Santa Cruz). The amount of protein expression
was quantified by the ChemiDoc XRS+ System (Bio-
Rad, Hercules, CA), and was expressed as the ratio
relative to β-actin protein.Immunoprecipitation and immunoblot analysis
Protein extracts from samples of the RVLM were
immunoprecipitated with an affinity-purified anti-
serum against IkBα (Cell Signaling) that was co-
njugated with protein G-agarose beads (Roche).
Immunoprecipitation was performed at 4 °C overnight
and the precipitated beads obtained after centrifuged
at 10,000 g for 30 s were washed three times with ice-
cold lysis buffer. The agarose beads resuspended in
the loading buffer were boiled for 10 min. After disso-
ciated from the beads, the immunoprecipitated protein
was subjected to immunblot analysis using an anti-
rabbit antiserum against SUMO-1 (Cell Signaling).
Measurement of transcriptional activity of NF-kB p65
Transcriptional activity of NF-kB p65 was measured by
a sensitive colorimetric assay (TransAM NF-kB p65;
Active Motif; Carlsbad, CA) according to the manufac-
turer’s protocol. Briefly, nuclear protein extracted from
the RVLM was incubated with an immobilized oligo-
nucleotide containing the NF-kB consensus-binding site
(5′-GGGACTTTCC-3′). This was followed by in-
cubation with a primary NF-kB p65 antibody, and a
secondary peroxidase-conjugated antibody at room
temperature. After a colorimetric reaction, the optical
density was read at 450 nm using an ELISA microtiter
plate reader.
Statistical analysis
All values are expressed as mean ± SEM. The averaged
value of MAP or HR calculated every 20 min after ad-
ministration of LPS or saline, the sum of power density
of BLF component in the AP spectrum over 20 min, and
protein expression level or the relative mRNA expres-
sion in the RVLM during each phase of experimental
endotoxemia, was used for statistical analysis. One-way
or two-way analysis of variance with repeated measures
was used to assess group means, followed by the
Scheffé multiple range test for post hoc assessment ofindividual means. P < 0.05 was considered to be statisti-
cally significant.
Results
Triphasic cardiovascular responses in experimental
endotoxemia model of brain death
Figure 1 showed that, similar to our previous studies
[29, 30, 36], intravenous administration of LPS
(10 mg kg−1) in our control animals pretreated with
microinjection bilaterally into RVLM of normal serum
(1:20) elicited a reduction (Phase I), augmentation
(Phase II; pro-life phase) and a secondary decrease
(Phase III; pro-death phase) in the power density of the
BLF component of AP signals. MAP underwent typically
a significant decrease during Phase I, followed by a re-
bound (Phase II) and progressive hypotension during
Phase III. Significant reduction in HR only took place to-
wards the last 40 min of our 300-min observation.
Upregulation of SUMO-1 and Ubc9 in the RVLM during
experimental brain death
Our first series of experiments evaluated the changes of
SUMO-1 and Ubc9 in the RVLM during experimental
brain death. Real-time PCR analysis revealed that, com-
pared to sham-control and saline-controls, the sumo1 or
ubc9 mRNA (Fig. 2) level in the RVLM was significantly
elevated in our experimental endotoxemia model. Simi-
larly, results from western blot analysis showed signifi-
cant augmentation of SUMO-1 monomer (Fig. 3a) or
Ubc9 (Fig. 3b) protein level in the RVLM. In addition,
there was a significant elevation in the amount of
SUMO-1-conjugated proteins (Fig. 3a).
Sumoylation in the RVLM plays a pro-life role during ex-
perimental brain death
Our second series of experiments employed immuno-
neutralization to establish a causal relationship between
augmented sumoylation and survival rate during experi-
mental brain death. At the dose (10 mg kg−1) used,
intravenous administration of LPS elicited approximately
28.6 % (4 of 14 animals) fatality within 300 min of ad-
ministration (Fig. 4). Pretreatment with microinjection
into the bilateral RVLM of an anti-SUMO-1 antiserum
(1:20) or anti-Ubc9 antiserum (1:20) 30 min before the
induction of experimental brain death resulted in 50.0 %
(7 of 14 animals) or 57.1 % (8 of 14 animals) death
within the same time-period (Fig. 4).
Sumoylation in the RVLM plays a pro-life role by amelior-
ating failure of brain stem cardiovascular regulation
Pretreatment by microinjection into the bilateral RVLM
of an anti-SUMO-1 or anti-Ubc9 antiserum (Fig. 1) sig-
nificantly potentiated the elicited hypotension or brady-
cardia by LPS. The same pretreatment also eliminated
Phase I Phase II Phase III
Fig. 1 Temporal changes in mean arterial pressure (MAP), heart rate (HR)
or power density of the low-frequency (BLF) component of AP spectrum
in rats that received pretreatment by microinjection bilaterally into the
RVLM of normal rat serum (NRS; 1:20), anti-SUMO-1 antiserum (SUMO-1
Ab; 1:20) or anti-Ubc9 antiserum (Ubc9 Ab; 1:20), followed by intravenous
administration of saline or LPS (10 mg kg−1). The three distinct phases
based on reduced (Phase I), augmented (Phase II) and a secondary
decreased (Phase III) power density of the BLF spectral component
induced by LPS are denoted on top of the figure. Values are mean ±
SEM of 7–8 animals per experimental group. *P< 0.05 versus NRS + saline
group, and +P< 0.05 versus NRS + LPS group at corresponding
time-points in the post hoc Scheffé multiple-range test. B = preinjection
baseline. Note that for clarity of illustration, data on pretreatment with
normal mouse serum in this and Figs. 4 to 6 were omitted because they
were comparable to those with NRS pretreatment
Fig. 2 Phasic fold-changes relative to sham-controls of sumo1 or ubc9
mRNA in the RVLM determined by real-time PCR after intravenous
administration of saline or LPS (10 mg kg−1). Tissue samples were
collected during the peak of Phases I, II or III in the LPS group; or 20 (I),
150 (II) or 300 (III) min in the saline group. Values are mean ± SEM of
triplicate analyses on individual samples obtained from 4–5 animals
per experimental group. *P < 0.05 versus sham-control group or
corresponding saline group in the post hoc Scheffé multiple-range test
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during the pro-life Phase II, and significantly enhanced
the reduction in BLF power towards zero level during
the pro-death Phase III.Conjugation of SUMO-1 with IkBα attenuates NF-kB acti-
vation in RVLM during experimental brain death
We reported previously [30] that activation of NF-kB
preferentially upregulates NOS II in the RVLM during
experimental brain death. Our fourth series of experi-
ments investigated whether SUMO-1 may impede this
cellular process by inactivation of NF-kB via con-




















Fig. 3 Representative western blots (insets) or percentage of SUMO-1
monomer and SUMO-1 conjugate (a) or Ubc9 (b) relative to β-actin
detected in the RVLM during Phases I, II or III after intravenous
administration of saline or LPS (10 mg kg−1). Values are mean ± SEM of
duplicate analyses on individual samples obtained from 5–6 animals
per experimental group. *P < 0.05 versus corresponding saline group in
the post hoc Scheffé multiple-range test
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showed that the degree of sumoylated IkBα in the
RVLM was significantly reduced in our experimental
endotoxemia model. Likewise, there was a significant
decrease in protein expression of IkBα (Fig. 5b),
alongside elevated transcriptional activity of NF-kB
p65 in the RVLM (Fig. 5c).
In an attempt to confirm a causal relationship between
sumoylation of IkBα and attenuation of NF-kB activation
in the RVLM, co-immunoprecipitation experiments
(Fig. 5a) during experimental brain death showed that
pretreatment with microinjection bilaterally of an anti-
SUMO-1 or anti-Ubc9 antiserum (1:20) into the RVLM
exacerbated the already diminished sumoylated IkBα.
This pretreatment also potentiated the reduction in IkBα
protein level (Fig. 5b), and significantly enhanced NF-kB
p65 activation (Fig. 5c) in the RVLM.
Sumoylation reduces nitrosative stress in the RVLM
during experimental brain death
Our final series investigated whether sumoylation re-
duces the augmented nitrosative stress in the RVLM
during experimental brain death [28, 30]. Results from
western blot analysis (Fig. 6a) showed that the level of
NOS II or nitrotyrosine, an experimental index forFig. 4 Survival rate over 300 min of animals that received
pretreatment by microinjection bilaterally into the RVLM of an
antiserum directed against SUMO-1 (SUMO-1 Ab; 1:20) or Ubc9
(Ubc9 Ab; 1:20), or normal rabbit serum (NRS; 1:20), followed by
intravenous administration of saline or LPS (10 mg kg−1). Each group
contained 11–14 animals at the beginning of the experiment
Fig. 5 Results from immunoblot (IB) using an antiserum against SUMO-1
on proteins immunoprecipitated (IP) by an anti-IkBα antiserum from the
RVLM (a); western blot analysis of expression of IkBα relative to β-actin in
the RVLM (b); transcriptional activity of NF-kB p65 in the RVLM (c) after
intravenous administration of saline or LPS (10 mg kg−1); or animals that
received pretreatment by microinjection bilaterally into RVLM of NRS
(1:20), anti-SUMO-1 antiserum (SUMO-1 Ab; 1:20) or anti-Ubc9 antiserum
(Ubc9 Ab; 1:20) during Phase III in the experimental endotoxemia model
of brain death. Values are mean ± SEM of duplicate analyses on individual
samples obtained from 5–6 animals per experimental group. *P< 0.05
versus corresponding saline group and +P < 0.05 versus NRS + LPS
group in the post hoc Scheffé multiple-range test
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perimental endotoxemia model. Pretreatment with an
anti-SUMO-1 or anti-Ubc9 antiserum further potentiatedthis upregulation of NOS II or nitrotyrosine expression
(Fig. 6b) in the RVLM.
Discussion
Based on an experimental endotoxemia model that
mimics clinically comatose patients who succumbed to
systemic inflammatory response syndrome [23], the
present study provided two intriguing mechanistic in-
sights into brain death. First, sumoylation in the RVLM
is augmented during brain death, and one of the cellular
targets of SUMO-1 is IkBα. Second, sumoylation of IkBα
reduces its degradation, followed by attenuation of tran-
scriptional activation of NOS II synthesis by NF-kB and
subsequent formation of peroxynitrite. The resultant
diminution of nitrosative stress in the RVLM leads to
amelioration of the failure of brain stem cardiovascular
regulation that underpins cardiovascular depression dur-
ing experimental brain death.
SUMO proteins are highly conserved in a large num-
ber of species and are engaged in many eukaryotic cell
processes [39], including cell cycle regulation, transcrip-
tion, cellular localization, degradation and chromatin
organization [3]. It is well documented that global in-
creases in protein sumoylation occur in response to cel-
lular stress [6, 40–42], and the general consensus is that
this results in a protective action against stress. It is
therefore of interest that results from the present study
assigned a pro-life role to sumoylation at the RVLM in
our experimental endotoxemia model of brain death.
Based on real-time PCR and western blot analysis, we
demonstrated that SUMO-1 and Ubc9 expression at
mRNA and protein levels in the RVLM was significantly
elevated during experimental brain death. Immunoneu-
tralization of SUMO-1 or Ubc9 increased fatality and
significantly potentiated the elicited hypotension or
bradycardia. Most importantly, there was significant ex-
acerbation of the already reduced power density of the
BLF component towards zero level that is causally re-
lated to the manifestation of brain death in a clinical set-
ting [21, 23–25].
An elevation in SUMO-1 conjugation is not necessar-
ily accompanied by SUMO-2/3 conjugation or vice
versa. This suggests that sumoylation is controlled in a
substrate-specific manner [6]. For example, SUMO-1
modification of IkBα has been observed in Hela, COS7,
HEK 293 cell lines [8], rat mesangial cell [43] and CD37
null mouse lung tissue [44]. Immunoprecipitation exper-
iments in the present study also identified IkBα in the
RVLM as a conjugation target for SUMO-1. However,
despite the elevated amount of SUMO-1 conjugated
proteins, we found that sumoylation of IkBα and cyto-
solic presence of IkBα in the RVLM per se was signifi-
cantly decreased during experimental brain death. This



















Fig. 6 Representative western blots (insets), or percentage of NOS II or nitrotyrosine (NT) relative to β-actin in the RVLM detected after intravenous
administration of LPS (10 mg kg−1) in animals (a); or animals that received pretreatment by microinjection bilaterally into the RVLM of NRS (1:20),
anti-SUMO-1 antiserum (SUMO-1 Ab; 1:20) or anti-Ubc9 antiserum (Ubc9 Ab; 1:20) during phase III in the experimental endotoxemia model of brain
death (b). Values are mean ± SEM of duplicate analyses on individual samples obtained from 5–6 animals per experimental group. *P < 0.05 versus
corresponding saline group in the post hoc Scheffé multiple-range test. Note that in (a), dividing lines are placed on the representative gel images to
denote re-grouping of images from different parts of the same gel
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sumoylation and ubiquitination. Phosphorylation of
IkBα, at serine residues 32 and 36, results in its ubiquiti-
nation at lysine residues 21 and 22 and rapid degrad-
ation by the proteasome [45, 46]. Desterro et al. [9]
reported that SUMO-1 modification of IkBα also takes
place at lysine residue 21 and competes with ubiquitin
for the same target residue. Sumoylation can inactivate
NF-kB by conjugation with IkB [19, 20]; the sumoylated
pool of IkB is protected from ubiquitination, thereby
blocking its degradation and inhibits subsequent activa-
tion and nuclear translocation of NF-kB [9]. Our results
showed that whereas the level of IkBα protein in the
RVLM was reduced by approximately 26.5 % during
experimental brain death, immunoneutralization of
SUMO-1 or Ubc9 aggravated these reductions to
51.5 % or 56.6 %. It is therefore conceivable that despite
the protection from degradation offered by sumoyla-
tion, the tilt of balance in favor of ubiquitination of
IkBα accounts for our observed reduction in IkBα pro-
tein and sumoylated IkBα in the RVLM during experi-
mental brain death.
Our laboratory demonstrated previously that the pro-
gression towards brain death is causally related to tran-
scriptional upregulation of NOS II induced by NF-kB,
activated after IkB degradation via ubiquitination in the
RVLM [28–30, 47]. The eventual fatal culprit is nitrosa-
tive stress elicited by the formation of peroxynitrite via a
reaction between NOS II-produced NO and superoxideanion in the RVLM, of which underpins the defunct
brain stem cardiovascular regulation that precedes
hypotension and asystole during brain death [30, 31].
The present study revealed that sumoylation plays a
pro-life role in this process via protecting IkB from deg-
radation by ubiquitination, leading to amelioration of
NF-kB activity and the eventual reduction in nitrosative
stress in the RVLM in our endotoxemia model of experi-
mental brain death. In addition to protection against IkB
degradation, sumoylation may reduce NF-kB activity by
direct modification of the NF-kB subunit RelB [48].
Sumoylation is also reported [49] to decrease NOS II ex-
pression in LPS-induced inflammatory responses in as-
trocytes via modification of C/EBPβ at the NOS II
promoter. In a parallel study using an organophosphate
intoxication model of brain death [47, 50], we demon-
strated that SUMO-1 and NF-kB are present in RVLM
neurons. We also showed previously that the cellular
source of NOS II in the RVLM include neurons, astro-
cytes and microglia [31]. Together with observations
from the present study, it is conceivable that the afore-
mentioned interacting cascades between sumoylation,
NF-kB and NOS II may take place in neurons, astrocytes
and microglia at the RVLM.
Our laboratory revealed recently [30] that the ubiquitin-
proteasome system plays a double-edged sword role
in the maintained and defunct brain stem cardiovascular
regulation during experimental brain death via the tem-
poral balance between the continuous degradation and
Tsai et al. Journal of Biomedical Science  (2016) 23:65 Page 9 of 10progressively augmented synthesis of NOS II. We are
cognizant that, against our demonstration that sumoyla-
tion of IkBα leads to inactivation of NF-kB, promotion of
NF-kB activation in response to genotoxic stress via
SUMO-1 modification of NF-kB essential modifier
(NEMO, also known as IKKγ) has been demonstrated
[51]. We noted from the western blot image in Fig. 3a that
among the elevated SUMO-1-conjugated proteins was a
conspicuous band around 55 kDa. With a molecular
weight of 48 kDa [52], it is possible that sumoylation of
NEMO (SUMO-1 monomer has a molecular weight of
11 kDa) also takes place at the RVLM during experimental
endotoxemia. Likewise, SUMO-2/3 modification of the
same lysine residue 21 and 22 of IkBα, contrary to
SUMO-1, induces IkBα degradation and NF-kB activation
after TNFα-stimulation [11]. Whether sumoylation simi-
larly plays a double-edged sword role in the regulation of
NF-kB/NOS II/peroxynitrite cascade in the RVLM during
brain death requires further delineation.Conclusions
In conclusion, the present study provided novel findings
to support the notion that sumoylation in RVLM plays a
pro-life role during experimental brain death. Mechanis-
tically, we found that sumoylation of IkBα ameliorates
the defunct brain stem cardiovascular regulation that
underpins brain death by reducing nitrosative stress in
the RVLM via downregulation of the NF-kB/NOS II/per-
oxynitrite signaling cascade. In a parallel study using an
organophosphate intoxication model of brain death [50],
we demonstrated previously that sumoylation exerts its
pro-life role via inhibition of hypoxia-inducible factor-1α
degradation, leading to upregulation of NOS I/protein
kinase G cascade. Brain death, the legal definition of
death in many countries [53–56], is a phenomenon of
paramount medical importance. Since brain death is an
irreversible process, the identification that sumoylation
in the RVLM plays a crucial pro-life role in the progres-
sion towards brain death by inhibiting the NOS II/per-
oxynitrite cascade and enhancing the NOS I/protein
kinase G signaling offers new insights for devising
clinical management or therapeutic strategy against this
fatal eventuality.Abbreviations
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